<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>                  1     INDICATIONS AND USAGE<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        Tasigna is a kinase inhibitor indicated for: <BR>                        The treatment of newly diagnosed adult patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The study is ongoing and further data will be required to determine long-term outcome. (1.1)<BR>                        The treatment of chronic phase (CP) and accelerated phase (AP) Ph+ CML in adult patients resistant to or intolerant to prior therapy that included imatinib. (1.2)<BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.1     Newly Diagnosed Ph+ CML-CP<BR>                     <BR>                        Tasigna (nilotinib) is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The effectiveness of Tasigna is based on major molecular response and cytogenetic response rates [see Clinical Studies (14<BR>                           .1<BR>                           )]. The study is ongoing and further data will be required to determine long-term outcome.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.2     Resistant or Intolerant Ph+ CML-CP and CML-AP<BR>                     <BR>                        Tasigna is indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) in adult patients resistant or intolerant to prior therapy that included imatinib. The effectiveness of Tasigna is based on hematologic and cytogenetic response rates [<BR>                           s<BR>                           ee Clinical Studies (14<BR>                           .2<BR>                           )]. <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>